Liver, Pancreas and Biliary TractBiliary stone disease in patients receiving somatostatin analogs for neuroendocrine neoplasms. A retrospective observational study
-
Add time:09/03/2019 Source:sciencedirect.com
BackgroundSomatostatin analogs are the backbone of neuroendocrine neoplasms treatment. Biliary stone disease is a potentially severe adverse event of somatostatin analogs: an increased incidence has been reported in somatostatin analogs-treated acromegalic patients, but studies on patients with neuroendocrine neoplasms are lacking.
We also recommend Trading Suppliers and Manufacturers of somatostatin 34 (cas 132894-19-0). Pls Click Website Link as below: cas 132894-19-0 suppliers
Prev:Somatostatin promotes glucose generation of Ca2+oscillations in pancreatic islets both in the absence and presence of tolbutamide
Next:PreviewManaging Neuronal Ensembles: Somatostatin Interneuron Subpopulations Shape and Protect Cortical Neuronal Ensembles for Learning) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- PreviewManaging Neuronal Ensembles: Somatostatin Interneuron Subpopulations Shape and Protect Cortical Neuronal Ensembles for Learning09/04/2019
- Somatostatin promotes glucose generation of Ca2+oscillations in pancreatic islets both in the absence and presence of tolbutamide09/02/2019
- Original ContributionSomatostatin receptor SSTR2A and SSTR5 expression in neuroendocrine breast cancer☆☆☆☆☆☆09/01/2019
- Effect of somatostatin on prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis and hyperamylasemia: A systematic review and meta-analysis08/31/2019
- Research paperLigand design for somatostatin receptor isoforms 4 and 508/30/2019
- Somatostatin☆08/29/2019
- Research articleLong-lasting actions of somatostatin on pyramidal cell excitability in the mouse cingulate cortex08/28/2019
- Molecular Imaging and Nuclear MedicineMolecular imaging and therapy of somatostatin receptor positive tumors08/27/2019
